ganglionic nAChRs may be promising as a translational adjunctive therapy to avoid 45 HAAF in Type 1 diabetes mellitus. 46
An attenuated sympathoadrenal response following recurrent exposure to 50 hypoglycemia results in a pathological inability to recover from low blood glucose levels, 51 contributes to patient unawareness of hypoglycemia, and is associated with increased 52 mortality in Type 1 and possibly in Type 2 diabetic patients; a condition known as 53 hypoglycemia-associated autonomic failure (HAAF; (11, 1) . HAAF is recognized as a 54 major public health problem for patients with diabetes. It can also be induced in healthy 55 subjects, in infants and in animal models suggesting it may involve a maladaptive 56 response to repeated stress (20, 9, 12, 14) . 57
Despite the well-established role of hypoglycemia per se in the development of 58 HAAF, the mechanism(s) underlying the key feature of the pathogenesis of HAAF in 59 diabetes -the attenuated sympathoadrenal epinephrine response to falling plasma glucose 60 levels in a background of imperfect insulin replacement and impaired glucagon responses 61 (10) remains elusive. The reduced sympathoadrenal response in HAAF could result from 62 adaptations/maladaptations within central or peripheral neural-humoral networks that 63 regulate glucose homeostasis (7) or from alterations at the level of the afferent or efferent 64 components of the sympathoadrenal system. While central mechanisms contributing to 65 recurrently hypoglycemic animals, we randomly assigned chronically catheterized rats to 141 one of four experimental groups: recurrent saline (RS), recurrent cytisine (RC), recurrent 142 hypoglycemia (RH) and recurrent hypoglycemia + cytisine (CRH). Animals were 143 administered the study drug i.p. twice daily at 9 AM and 1 PM with either saline, 1mg/kg 144 cytisine, 2IU/kg insulin or a combination of cytisine and insulin (CRH group) with 145 cytisine given 30 min before the insulin (26, 36) . Animal chow was removed in all 146 groups for 3 hours during each antecedent drug protocol treatment. Blood glucose was 147 monitored from tail nick samples using handheld glucometers (AlphaTrak, Abbott 148
Laboratories, Chicago, IL) every 30-min throughout each hypoglycemic episode and if 149 needed, additional insulin was given in order to maintain glucose levels between 40 -50 150 mg/dL (Figure 3 ) in the RH and CRH groups. Animals were rescued with food or 151 dextrose per os if blood glucose levels dropped below target values. Control groups (RS 152 and RC) underwent the same procedure to ensure uniform exposure to handling stress for 153 all groups. All antecedent treatments were for three consecutive days as illustrated in 154
Figure 2. On day 3, only the morning treatment was given to allow the animals to fully 155 recover before being fasted overnight prior to the clamp procedure on day 4. On day 4, all 156 four groups underwent a 90 min hyperinsulinemic-hypoglycemic glucose clamp (22, 23) .
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(50mU/kg/min; Eli Lilly, Indianapolis, IN) and a variable 20% dextrose infusion were 164 started and plasma glucose levels were monitored every five minutes to guide dextrose 165 infusion and maintain target glucose levels at around 45 mg/dL for 90 min (Figure 4; ref. 166 22, 23) . Blood samples were collected at 30 min intervals throughout the study for 167 subsequent measurement of plasma glucagon, catecholamine, and corticosterone 168 responses. For measuring plasma insulin levels blood samples were collected at the 169 beginning and at the end of the glucose clamp. At the end of the study, animals were 170 provided with food to recover from the hypoglycemic episode and were then sacrificed 5 171 hrs after initiation of the hyperinsulinemic-hypoglycemic clamp with an overdose of i.v. 172 sodium pentobarbital followed by decapitation. The adrenal medullae were then 173 dissected, immediately frozen and stored at -80 0 C degrees until further analyses. 174
To determine whether there was a separate effect of re-feeding on TH mRNA 175 expression, we conducted a parallel set of studies in a smaller cohort of animals (n=3 for 176 each of the four treatment groups described above) whereby we maintained the 177 hypoglycemic clamp for the entire 5 hour period before sacrificing the animals (Fig. 6 B) . 178
Analytical methods: 179
Hormone analyses: Plasma glucagon, insulin and corticosterone were determined 180 using commercially available radioimmunoassay kits from Linco Research, St. Charles, 181 MO and Diagnostic Products, Los Angeles, CA (8). Plasma epinephrine and 182 norepinephrine concentrations were determined using a competitive enzyme 183 immunoassay (Rocky Mountain Diagnostics, Colorado Springs, CO) as described (44 
RESULTS
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Cytisine modestly stimulates epinephrine secretion and elevates adrenal TH 201 gene expression in vivo: Compared to saline, cytisine (0.3 to 3mg/kg, i.p., ref. 26, 36) 202 induced modest (but significant) increases in plasma epinephrine levels in a dose-203 dependent manner ( Figure 1A ). This rise was associated with a dose -dependent increase 204 in adrenomedullary TH mRNA levels ( Figure 1B) indicating cytisine has the capacity to 205 enhance both secretion and de novo synthesis of epinephrine. These effects of cytisine 206 (3mg/kg) were significantly less when compared to nicotine (1mg/kg) or insulin-induced 207 release of acetylcholine during hypoglycemia (peak epinephrine values of 110±10 pg/ml, 208 1200±122 pg/ml and 3310±140 pg/ml, respectively) which is consistent with its limited 209 potency to activate nicotinic receptor-mediated functions (36). Together, our data 210 suggests that cytisine acts as a partial agonist on adrenal postganglionic nicotinic 211 receptors in vivo serving two biologically important functions -to enhance the secretion 212 and de novo synthesis of epinephrine. As the effects of cytisine appeared to plateau at a 213 dose of 1mg/kg, this dose was used in the remaining studies. 214
Can cytisine improve the counterregulatory defect caused by insulin-induced 215 recurrent hypoglycemia? Daily plasma glucose concentrations during the recurrent 216 periods of treatment for all experimental groups are summarized in Fig. 3 . There were no 217 significant differences in the level of hypoglycemia that was achieved between the RH 218 and CRH groups. Similar plasma glucose levels were also obtained for the control groups 219 -RS and RC. It should be mentioned that animals from all experimental groups 220 displayed similar weight changes throughout treatments (data not shown). 221
Plasma glucose and insulin levels during the hypoglycemic clamp: Target blood glucose 222 levels (50 mg/dL) were achieved by 30 minutes and were similarly maintained at this 223 level in all groups ( Figure 4A ). Also, there was no significant difference in plasma insulin 224 levels at baseline or after the clamp between treatment groups during the study (Table 1) . 225
These observations indicated that all animals were exposed to identical glucose and 226 insulin stimuli during the glucose clamp portion of the protocol, differing only by their 227 antecedent drug intervention history in the preceding 3 days. The glucose infusion rates 228 are shown on Fig. 4B . Area under the curve (AUC) was calculated according to (43) . 229
Total exogenous glucose requirements in the RH group (AUC value of 772±85.79 230 mg/kg) were significantly higher compared to controls (calculated AUC for both, RS and 231 each bout of hypoglycemia (CRH group) the total amount of glucose administered (AUC 233 value of 578.1±30.9) was lowered compared to RH group. 234
Effect of cytisine on counterregulatory hormone release following insulin-induced 235 recurrent hypoglycemia: There were no statistically significant differences in baseline 236 blood levels of counterregulatory hormones between the four treatment groups ( Figure 5) . 237
In response to hypoglycemia, plasma concentrations of epinephrine ( Figure 5A ) and 238 glucagon ( Figure 5C 
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Recurrently hypoglycemic animals (RH) had a significantly attenuated glucagon response 249 and this response was completely restored with cytisine treatment (CRH group). Cytisine 250 treatment alone in the absence of recurrent hypoglycemia (RC group) did not affect the 251 glucagon response (Fig. 5C ). 252
Baseline norepinephrine values and its increased increments during the 253 hypoglycemic clamp were not significantly different between the four experimental 254 groups ( Fig. 5B ) and were consistent with previously published results for RS and RH,(39). These results suggest that sympathetic postganglionic outflow was similar in all 256 experimental conditions and was not significantly affected by cytisine. 257
Similarly, baseline corticosterone values in all groups were not different from one 258 another and showed the expected normal diurnal levels for that time of day (~100 ng/ml, 259 see Figure 5D ). During the hypoglycemic clamp, plasma corticosterone levels increased 260 in all groups (p < 0.05 vs. corresponding baseline) but again, the responses were not 261 different between treatment groups. 262
Relative adrenal TH mRNA levels parallel the magnitude of the epinephrine 263 response: The release of catecholamines from the adrenal medulla in response to stress is 264 accompanied by compensatory increases in their biosynthesis via mechanisms that result 265 in increased TH mRNA, TH protein and enzyme activity in order to maintain the 266 releasable pool of cellular catecholamines at constant levels (24). Adrenal TH mRNA 267 levels increased significantly in all animal groups that underwent the hypoglycemic 268
clamp, compared to non-manipulated controls (CON). However, the rise in TH mRNA 269 was significantly less in the group exposed to twice daily episodes of antecedent 270 hypoglycemia (RH vs. RS; **p < 0.05). The observed changes in TH mRNA levels in 271 response to acute and recurrent hypoglycemia in the presence of cytisine (RC and CRH) 272
were not significantly different from RS group and correlated with peak plasma 273 epinephrine responses (Pearson's coefficient of 0.9835). Importantly, the CRH group 274
showed an improving trend compared to the RH group (p=0.06, Figure 6A ). 275
In a control experiment, animals were sacrificed at the desired time point for 276 tissue collection (5 hours) but without the recovery and re-feeding interventions (6B). A 277 similar pattern was obtained for all experimental groups indicating that the observed 278 responses were in fact due to differences arising from the antecedent exposure rather than 279 during the period of recovery following the hypoglycemic clamp. intriguing and offer a proof-of-concept in the peripheral nervous system that parallels the 293 previously recognized effects of nicotinic receptor partial agonists on central 294 catecholaminergic cell responses (11, 36, 37, 29, 30) . 295
Transsynaptic Modulation: Cytisine has been used since the 1960s as an aid for 296 smoking cessation in eastern and central European countries (17), but there is only a 297 small amount of data on its efficacy since its clinical utility is limited by its affinity for 298 other nAChR subtypes and limited blood-brain barrier penetration (36). Its potential 299 effects on peripheral nAChR function in vivo during whole animal responses have not 300 been previously reported. Our data are consistent with cytisine functioning as a typicalpartial agonist at postsynaptic nicotinic receptors of the adrenal medulla which can 302 induce catecholamine release (epinephrine) and de novo catecholamine synthesis 303 (increased adrenal TH mRNA levels). In addition, as expected, the magnitude of the 304 response is significantly lower than that of a full agonist(s) compare to either, 305 exogenously administered nicotine (Figure 1 ) or insulin induced acetylcholine release 306
( Figures 5A, 6 ). 307
Although binding and antagonism tests were not conducted in our studies, other 308 reports have shown that cytisine has similar binding affinity for adrenal α3β4 receptors 309 (27) as nicotine and no affinity for muscarinic or histamine receptors (2, 27) . 310
Furthermore, in PC12 cells (44) and in perfused adrenal glands, cytisine stimulates 311 catecholamine release in a dose-, time-and Ca 2+ -dependent manner (27, 49) and blocks 312 the actions of acetylcholine on nicotinic receptors through a competitive mechanism (32). 313
Our in vivo data shows that recurrent exposure to cytisine produces a modest 314 reduction in epinephrine secretion in response to acute hypoglycemia (as observed in the 315 RC experimental group, Figure 5) , consistent with it's partial agonist properties. When 316 animals were pre-treated with cytisine before each hypoglycemic episode in an animal 317 model of HAAF, the circulating epinephrine responses to subsequent bouts of 318 hypoglycemia were significantly improved (CRH vs. RH group, Fig. 5 ). Given that 319 ganglionic blockers and/or surgical ablation of autonomic sympathetic nerve inputs 320 markedly impair autonomic activation of the adrenal medulla during insulin-induced 321 hypoglycemia in both animal models and in humans (42), it is reasonable to conclude, 322 that cytisine most likely acts on post-ganglionic neuronal nAChR to modulate theirInsulin-induced hypoglycemia is a potent activator of the adrenomedullary 325 hormonal system (19). This activation is mediated by indirect reflex excitation of the 326 splanchnic nerve, which evokes large increases in catecholamine secretion (resulting in 327 up to 70% of epinephrine content depletion (47), accompanied by activation of TH 328 enzyme and compensatory catecholamine biosynthesis in the adrenal medulla to maintain 329 cellular catecholamine levels constant (41). As an index of catecholamine biosynthesis, 330
we quantified changes in adrenal TH mRNA (25). After the hypoglycemic clamp, TH 331 mRNA levels increased in all treatment groups compared to non-manipulated controls. 332
However, the rise in TH mRNA was significantly less in the RH group. This is consistent 333 with reports showing reduced in situ staining of TH and PNMT mRNA levels in the 334 adrenal medullas of diabetic rats that underwent the same recurrent hypoglycemia 335 paradigm (HAAF) as our model (22, 23) . Our quantitative TH mRNA data suggests that 336 following recurrent exposure to hypoglycemia, a molecular mechanism may exist that 337 can limit the capacity to replenish the adrenal pool of epinephrine. The possible 338 contribution of non-cholinergic receptor activation by presynaptic neuropeptides that are 339 co-localized and co-released with acetylcholine (24, 41) is another outstanding question 340 that needs to be addressed in future studies. Importantly, the effect of cytisine on TH 341 mRNA levels during acute (RC) or recurrent (CRH) hypoglycemia correlated with the 342 corresponding rates of epinephrine secretion and it was consistent with partial agonist 343 properties of the drug suggesting future research may prove instructive as a potential 344
therapy. 345
Nicotinic receptor tachyphylaxis is an unlikely mechanism to explain these results 346 for several reasons: First, it is known that α3β4 nAchRs are only moderately susceptibleto desensitization (34). Secondly, if desensitization had occurred, one would expect the 348 opposite effect (or no effect) in the CRH group. Thirdly, using intact adrenal glands in 349 Hormonal pathways: Plasma glucagon levels were attenuated during HAAF as 360 previously reported (4); while in contrast, similar increments in glucagon were obtained 361 in the remaining experimental groups. Notably, treatment with cytisine substantially 362 improved the circulating glucagon responses in recurrently hypoglycemic animals to 363 nearly the same levels as seen in the saline group. Glucagon release from pancreatic α-364 cells is regulated by a number of factors including glucose, insulin and somatostatin 365 secreted from neighboring β-and delta-cells, as well as by redundant autonomic inputs 366 from sympathetic, parasympathetic and sympathoadrenal neurotransmitters and 367 neuropeptides (rev. in (42). How cytisine treatment influences the relative contribution 368 from each of these inputs remains to be elucidated. 369
No differences in plasma corticosterone concentrations were observed between 370 the four treatment groups suggesting similar levels of stress exposure and responsiveness 371 of the HPA axis under all experimental conditions. Although several studies in non-372 diabetic humans (13) and normal rats (38) showed that elevated plasma glucocorticoids 373 during antecedent hypoglycemia contribute to the development of HAAF (18), we did not 374 observe elevated baseline corticosterone levels in our model of HAAF. 375
A limitation of our approach is that our current data cannot exclude a direct or 376 indirect effect of cytisine working through central nervous system nAChR's; although it 377 has been reported that cytisine has limited brain penetrance (36). Cholinergic receptors 378 are crucial for acetylcholine neurotransmission in the CNS, and increased expression of 379 α7 nAChR has been observed in the cerebellum of diabetic and control rats during 380 hypoglycemia (3). We are not aware of any data supporting nAChR-mediated regulation 381 of glucose sensing neurons, but nAChRs in general can modulate neuronal activity at the 382 microcircuit synaptic level, by altering the cell processing of information and by 383 influencing the velocity of action potentials or the synchrony of communication between 384 brain areas (5). Further studies are needed to evaluate the potential peripheral versus 385 central effects of cytisine, pertinent to glucose counterregulation. It should be noted that 386 in some human studies a direct muscarinic cholinergic inhibition of hepatic glucose 387 production has been observed (6) but our current data reveal that reducing cholinergic 388 neurotransmission at nicotinic receptors improves counterregulatory responses and 389 perhaps also hepatic glucose production, although the latter was not evaluated. 390
In summary, we showed that activation of nAChRs during prior, antecedent bouts 391 of hypoglycemia can reduce the capacity of the adrenal medulla to replenish the 392 releasable pool of catecholamines (compare TH mRNA in RH vs RS group, Fig. 6A 
